阿托伐他汀联合非诺贝特治疗糖尿病并高脂血症的疗效分析

Analysis of the Efficacy of Atorvastatin Combined with Fenofibrate in the Treatment of Diabetes and Hyperlipidemia

目的探讨阿托伐他汀联合非诺贝特治疗糖尿病并高脂血症的疗效。方法方便选择2018年6月—2020年5月该院收治的糖尿病并高脂血症患者130例,以随机数字表法将其分为两组。对照组65例,应用阿托伐他汀钙片治疗;研究组65例,在此基础上应用非诺贝特治疗。对比两组患者的临床疗效,治疗前后的血脂水平、血糖水平,以及不良反应情况。结果两组患者总有效率对比中,研究组(96.92%)较对照组(86.15%)更高,差异有统计学意义(χ^(2)=4.866,P<0.05)。研究组LDL-C(2.5±0.1)mmol/L、TC(4.6±0.5)mmol/L、TG(1.2±0.5)mmol/L较对照组(3.3±0.2)、(6.5±0.3)、(2.5±0.8)mmol/L更低,差异有统计学意义(t=28.844,26.271,11.110,P<0.01),HDL-C(1.3±0.2)mmol/L较对照组(1.0±0.3)mmol/L更高,差异有统计学意义(t=6.708,P<0.05)。治疗后,研究组FPG(4.6±1.2)mmol/L与2 hPG(6.2±1.2)mmol/L较对照组(5.6±1.3)mmol/L、(7.8±0.9)mmol/L更低,差异有统计学意义(t=4.557,8.600,P<0.05)。不良反应发生率对比中,对照组(4.62%)与研究组(1.54%)对比,差异无统计学意义(χ^(2)=0.258,P>0.05)。结论阿托伐他汀联合非诺贝特治疗糖尿病并高脂血症疗效可靠,可以有效调节患者的血压与血脂水平,安全性佳,适于临床应用。

Objective To explore the efficacy of atorvastatin combined with fenofibrate in the treatment of diabetes and hyperlipidemia.Methods A total of 130 patients with diabetes and hyperlipidemia admitted to the hospital from June 2018 to May 2020 were conveniently selected and divided into two groups by random number table.65 cases in the control group were treated with atorvastatin calcium tablets,and 65 cases in the study group were treated with fenofibrate on this basis.The clinical efficacy of the two groups of patients,blood lipid levels and blood glucose levels before and after treatment,and adverse reactions were compared.Results In the comparison of the total effective rate between the two groups,96.92% of the study group was higher than 86.15% of the control group,the difference was statistically significant(χ^(2)=4.866,P<0.05).LDL-C(2.5±0.1)mmol/L,TC(4.6±0.5)mmol/L,TG(1.2±0.5)mmol/L in the study group were compared with those in the control group(3.3±0.2)mmol/L,(6.5±0.3)mmol/L and(2.5±0.8)mmol/L were lower,the difference was statistically significant(t=28.844,26.271,11.110,P<0.05),HDL-C(1.3±0.2)mmol/L was better than the control group(1.0±0.3)mmol/L higher,the difference was statistically significant(t=6.708,P<0.05).After treatment,FPG(4.6±1.2)mmol/L and 2 hPG(6.2±1.2)mmol/L in the study group were lower than those in the control group(5.6±1.3)mmol/L and(7.8±0.9)mmol/L,the difference was statistically significant(t=4.557,8.600,P<0.05).In the comparison of the incidence of adverse reactions,there was no significant difference between 4.62% of the control group and 1.54% of the study group(χ^(2)=0.258,P>0.05).Conclusion Atorvastatin combined with fenofibrate has a reliable curative effect in the treatment of diabetes and hyperlipidemia.It can effectively regulate the blood pressure and blood lipid levels of patients with good safety and is suitable for clinical application.